Open AccessTBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker
Author(s) -
E.L. Mayer,
V. Abramson,
R. Jankowitz,
C. Falkson,
P.K. Marcom,
T. Traina,
L. Carey,
M. Rimawi,
J. Specht,
K. Miller,
V. Stearns,
N. Tung,
C. Perou,
A.L. Richardson,
K. Componeschi,
L. Trippa,
Z. Tan-Wasielewski,
K. Timms,
I. Krop,
A.C. Wolff,
E.P. Winer
Publication year - 2020
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/pdj8-zw07
Subject(s) - homologous recombination , cisplatin , breast cancer , biomarker , paclitaxel , triple negative breast cancer , homologous chromosome , oncology , medicine , cancer research , cancer , chemotherapy , biology , gene , genetics